Financière de Tubize

UCB is a Belgium-based biopharmaceutical company focused on developing therapies for central nervous system and immunology diseases. It maintains a broad portfolio across neurology and immunology, including treatments for epilepsy (Vimpat, Briviact, Keppra), Parkinson's disease and restless legs syndrome (Neupro), and autoimmune conditions such as inflammatory diseases (Cimzia) and psoriasis-related indications (bimekizumab, Evenity for osteoporosis). The company also markets medicines for allergies (Zyrtec, Xyzal), narcolepsy (Xyrem), and other conditions, and is pursuing innovative therapies such as Nayzilam for seizure clusters and newer agents like padsevonil, rozanolixizumab, UCB7858, UCB0599, and UCB0107. It engages in contract manufacturing and collaborates with academic and industry partners, including a multi-year collaboration with Stanford Medicine and partnerships with Sanofi, Amgen, Biogen, Otsuka, and doc.ai to advance patient value. Founded in 1928 and headquartered in Brussels, UCB integrates research, development, and manufacturing to address neurological and immune-related diseases worldwide.